Urology
Volume 75, Issue 3 , Pages 502-509, March 2010

Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial

  • E. David Crawford

      Affiliations

    • Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado
    • Corresponding Author InformationReprint requests: E. David Crawford, MD, Division of Urologic Oncology, Departments of Surgery, Urology and Radiation Oncology, University of Colorado Health Sciences Center, Mail Stop #F710, PO Box #6510, Aurora, CO 80045
    • ,
  • Gerald L. Andriole

      Affiliations

    • Division of Urologic Surgery, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri
    • ,
  • Michael Marberger

      Affiliations

    • Department of Urology, Medical University of Vienna, Vienna, Austria
    • ,
  • Roger S. Rittmaster

      Affiliations

    • Biomedical Data Sciences, GlaxoSmithKline, Research Triangle Park, North Carolina

Received 8 January 2009; accepted 17 May 2009. published online 25 December 2009.

The landmark Prostate Cancer Prevention Trial (PCPT) generated interest in the potential health benefits and cost of reducing prostate cancer risk—specifically, the potential role of 5α-reductase inhibitors. However, the PCPT raised several unanswered questions, including the cause and significance of the increased incidence of high-grade tumors associated with finasteride. In the present study, we review the PCPT findings and unanswered questions, next steps in this field, and ongoing prostate cancer prevention trials addressing these unanswered questions. Particular emphasis is placed on the design of the second large-scale trial of a 5α-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Medical writing support in the preparation of this manuscript was provided by Katherine Carpenter and was funded by GlaxoSmithKline.

PII: S0090-4295(09)00931-5

doi:10.1016/j.urology.2009.05.099

Urology
Volume 75, Issue 3 , Pages 502-509, March 2010

Article Tools

* Image Usage & Resolution